30.00
+3.27%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Senhwa Biosciences
Its shares trade on Taipei Exchange under the ticker 6492.TWO. It has been listed since 4 December 2014. In the fiscal year to 31 December 2025, it reported revenue of TWD 1.1m and a net loss of TWD 264.8m. At that date it held total assets of TWD 819.3m and shareholders' equity of TWD 761.0m.
Senhwa Biosciences, Inc. engages in the research and development of anticancer drug and active pharmaceutical ingredient. The company is headquartered in Taipei, New Taipei. The company went IPO on 2014-12-04. The firm's main development projects include the CX-5461, for the treatment of hematologic cancers and breast cancers, as well as the CX-4945, for the treatment of cholangiocarcinoma. The firm has not generated any revenues yet.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Dec 2014
- Website
- senhwabio.com/en ↗
Leadership
Pay as last reported
- Mr. Benny HuChairman of the Board, since 2012
- Ms. Sarah ChangChief Financial Officer, Executive Deputy General Manager, Head of Finance & Administration, Corporate Governance Officer
- Xiaohui LuoActing Chief Operating Officer
- Mr. Jin Ding HuangChief Scientific Officer, General Manager, since 2022
- Pinyan HuangActing General Manager, Deputy General Manager, Chief Medical Officer
- Mr. Chien-Fu ChenDirector
- Yulian FengDirector
- Ms. Yeu-Chuyr ChangIndependent DirectorTWD 600,000
- Mr. Tong-Young LeeIndependent DirectorTWD 600,000
- Mr. Yung-Lin MaIndependent DirectorTWD 600,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Senhwa Biosciences Inc. has a product line including CX-5461 for hematologic cancers and breast cancers.
- The company is headquartered in Taipei, Taiwan, serving the Health Care sector.
- The firm's IPO in December 2014 established its public market presence.
Weaknesses
- The company has not generated any revenues yet, indicating early-stage commercialization challenges.
- Senhwa Biosciences Inc. operates solely within the Biotechnology industry segment.
- The firm's product development stage for CX-4945 and CX-5461 remains in progress without revenue generation.
Opportunities
- The Health Care sector in Taiwan presents growth potential for biotechnology firms like Senhwa Biosciences Inc.
- Expanding the CX-5461 development for hematologic cancers could attract investment.
- The Biotechnology industry in Taiwan may offer collaborative opportunities for research and development.
Threats
- The lack of revenue generation poses a financial risk for Senhwa Biosciences Inc. in the competitive Health Care sector.
- Dependence on a limited product pipeline (CX-5461 and CX-4945) increases vulnerability to development setbacks.
- The Biotechnology industry faces regulatory challenges that could delay product approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.